Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency VirusEmma M. Kileel, Steven Grinspoon, Princy Kumar et al.|Open Forum Infectious Diseases|2021Cited by 38
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)Emma M. Kileel, Steven Grinspoon, Carlos Malvestutto et al.|Clinical Infectious Diseases|2023Cited by 8
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M. Kileel, Heather J Ribaudo, Carlos Malvestutto et al.|The Lancet HIV|2026Cited by 2
HEalth Record Optimization for Identifying Candidates for HIV PRe-Exposure Prophylaxis: A Community-Informed Approach to Model DevelopmentMeredith E. Clement, Sarah M. Wilson, Jennifer Thomas et al.|AIDS Patient Care and STDs|2025Cited by 1